Forest Laboratories (FRX) has received a request from the New York State Attorney General for any information that may exist with respect to off-label clinical trials or promotion of its products.

The company said after the bell Tuesday that the request states that the attorney general is concerned that Forest may be in violation of New York law. Forest said that the request was not a subpoena, but that the company will fully cooperate with the request and believes it has complied with all applicable laws.

Forest is taking heat from the

Food and Drug Administration

TST Recommends

for not publishing results from a clinical trial of one of its antidepressants, and it is also being pressured by the FDA, along with eight other manufacturers, to put bold warnings on labels about possible suicidal thinking, although no direct link has been established.

According to the

Wall Street Journal

, Forest has said the "overall analysis" of the clinical trial data shows there is no increased risk of suicidality or worsening of depression associated with citalopram, the chemical name for its Celexa drug.

Shares of Forest closed up 29 cents Tuesday to $57.65.